What is SeqOnce BioScience?
SeqOnce BioScience operates at the intersection of biotechnology and high-performance research instrumentation. The company specializes in the development of advanced qPCR and library preparation kits, which are essential for modern Next-Generation Sequencing (NGS) workflows. Their product suite is engineered to optimize laboratory efficiency, offering researchers the ability to achieve faster, more reliable results in multiplexing environments. Beyond its commercial offerings, SeqOnce distinguishes itself through a dual-focus approach: providing high-quality reagents while simultaneously applying its proprietary assay technology to critical conservation efforts, specifically targeting the protection of endangered species. This unique blend of commercial genomics and environmental stewardship provides the company with a distinct market identity, appealing to both academic research institutions and conservation-focused biological organizations.
How much funding has SeqOnce BioScience raised?
SeqOnce BioScience has raised a total of $1M across 1 funding round:
Angel/Seed
$1M
Angel/Seed (2018): $1M, investors not publicly disclosed
Key Investors in SeqOnce BioScience
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SeqOnce BioScience?
With this major enterprise-level funding, SeqOnce BioScience is well-positioned to scale its manufacturing capabilities and expand its footprint in the global genomics market. The strategic allocation of these funds will likely focus on accelerating the R&D pipeline for next-generation NGS products and enhancing the company's technical support infrastructure to meet rising demand. As the industry shifts toward more rapid, automated diagnostic solutions, SeqOnce is poised to leverage its existing technical expertise to capture additional market share. Future growth trajectories will likely involve deepening its penetration into clinical research markets, where the demand for high-throughput, cost-effective qPCR solutions remains robust. By maintaining its commitment to rapid customer response and technical excellence, the firm is set to solidify its role as a key enabler of genomic discovery and biodiversity preservation.
See full SeqOnce BioScience company page
